HolderBook

Aisling Capital Management LP

Reported holdings as of Q2 2026, from 31 quarterly filings.

CIK
1766721
Reported value
$471.6M
Positions
14
Top 10 weight
99.0%
Filed
2026-08-13
Days after quarter end
44

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
BRIDGEBIO PHARMA INCBBIO$341.8M4,589,61172.48%-6.87pp29q-9.8%-$37.2M
MONTE ROSA THERAPEUTICS INCGLUE$37.6M1,555,6647.98%+2.61pp21qHELD
SYNDAX PHARMACEUTICALS INCSNDX$28.8M1,316,8066.10%-0.35pp26qHELD
COMPASS PATHWAYS PLCCMPS$20.3M1,432,3364.30%+2.63pp12qHELD
BICARA THERAPEUTICS INCBCAX$16.9M568,9193.58%+1.21pp8qHELD
BRIDGEBIO ONCOLOGY THERAPEUTBBOT$7.8M1,018,0181.64%-0.27pp4qHELD
SCHOLAR ROCK HLDG CORPSRRK$4.2M77,0310.90%+0.10pp4qHELD
UROGEN PHARMA LTDURGN$4.0M108,0000.84%+0.44pp3qHELD
BIOMEA FUSION INCBMEA$3.0M2,048,7570.64%-0.02pp21qHELD
ACLARIS THERAPEUTICS INCACRS$2.3M434,4550.49%+0.15pp31qHELD
EUPRAXIA PHARMACEUTICALS INCEPRX$2.1M325,0000.46%-0.04pp2qHELD
VTV THERAPEUTICS INCVTVT$1.9M50,0000.40%-newNEW
MARKER THERAPEUTICS INCMRKR$478.3K325,3700.10%+0.01pp13qHELD
ONKURE THERAPEUTICS INCOKUR$404.0K88,6070.09%+0.01pp7qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 100.0%
 
SectorValueShare
Biotech & Pharma$471.6M100.0%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$471.6M14101099.0%44
Q1 2026$476.3M13130199.5%35
Q4 2025$478.9M13101299.6%41
Q3 2025$456.4M14210199.4%43
Q2 2025$359.7M13020099.6%44
Q1 2025$288.5M13011299.5%43
Q4 2024$281.8M15110298.4%43
Q3 2024$261.1M16100097.3%44
Q2 2024$231.1M15100297.8%39
Q1 2024$295.5M16100198.0%44
Q4 2023$335.2M16000198.5%38
Q3 2023$242.7M17200196.5%44
Q2 2023$204.1M16100197.4%42
Q1 2023$207.8M16002097.5%39
Q4 2022$151.5M16001197.1%40
Q3 2022$150.6M17001295.6%34
Q2 2022$140.2M19002293.5%41
Q1 2022$185.3M21002089.7%40
Q4 2021$283.5M21001086.1%49
Q3 2021$501.5M21001089.8%43
Q2 2021$624.6M21600089.0%37
Q1 2021$555.6M15220396.2%44
Q4 2020$582.3M16101097.6%36
Q3 2020$313.0M15211096.7%43
Q2 2020$262.0M13020198.3%41
Q1 2020$229.6M14120097.8%41
Q4 2019$261.0M13010097.6%37
Q3 2019$191.8M13030197.0%44
Q2 2019$234.1M14220095.4%44
Q1 2019$131.3M12031094.9%50
Q4 2018$94.9M12000096.1%39

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.